Pediatric-plan strategist must resolve whether the 505(b)(2) bridge

Situation

An AdCom briefing document that overstates subgroup findings put complete-response-letter deficiency list in front of pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT. This Pharma & Life Sciences / FDA Response and Labeling close is the 505(b)(2) bridge is from complete-response-letter deficiency list, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

Decision

Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Authorize Proceed under protocol now; complete-response-letter deficiency list already has the discriminator after an AdCom briefing document that overstates subgroup findings.
• Keep Pause the pathway in force until complete-response-letter deficiency list is completed after an AdCom briefing document that overstates subgroup findings for pediatric-plan strategist.
• Treat complete-response-letter deficiency list as Escalate safety review because both readings appear after an AdCom briefing document that overstates subgroup findings.
• Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the page the 505(b)(2) bridge is turns on in complete-response-letter deficiency list.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is.
• Check whether complete-response-letter deficiency list supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences FDA Response and Labeling file, read complete-response-letter deficiency list against an AdCom briefing document that overstates subgroup findings and write the one fact that would move the 505(b)(2) bridge is for pediatric-plan strategist.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT.